The global Dosage Form Development Service market size is predicted to grow from US$ 1266 million in 2025 to US$ 1798 million in 2031; it is expected to grow at a CAGR of 6.0% from 2025 to 2031.
Dosage form development service refers to research and development services provided to pharmaceutical companies or research institutions for drug dosage forms. Dosage form refers to the administration form of a drug, i.E., the form in which a drug is prepared for use by patients. Common dosage forms include tablets, capsules, injections, liquids, ointments, etc. The choice of dosage form has a significant impact on drug efficacy, stability, and patient acceptability. Dosage form development services typically include the screening and optimization of dosage forms, the design and adjustment of formulation recipes, and the research and optimization of production processes. Through dosage form development services, pharmaceutical companies can develop drug dosage forms that are more suitable for patient needs and clinical applications, improving drug efficacy and safety while reducing production costs. Additionally, these services can help companies obtain relevant patent protection, enhancing their market competitiveness.
United States market for Dosage Form Development Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Dosage Form Development Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Dosage Form Development Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Dosage Form Development Service players cover Ascendia, Recipharm, Aurigene Services, Pirama, 厂别谤谩苍, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淒osage Form Development Service Industry Forecast鈥� looks at past sales and reviews total world Dosage Form Development Service sales in 2024, providing a comprehensive analysis by region and market sector of projected Dosage Form Development Service sales for 2025 through 2031. With Dosage Form Development Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dosage Form Development Service industry.
This Insight Report provides a comprehensive analysis of the global Dosage Form Development Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Dosage Form Development Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Dosage Form Development Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dosage Form Development Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dosage Form Development Service.
This report presents a comprehensive overview, market shares, and growth opportunities of Dosage Form Development Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
Pre-Formulation Services
Late Phase Formulation Development Services
Segmentation by Application:
Oral Dosage Form
Injectable Dosage Form
Transdermal Dosage Form
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Ascendia
Recipharm
Aurigene Services
Pirama
厂别谤谩苍
SGS
NerPharMa
Scantox
Protheragen-ING
BDD Pharma
Evonik
Dalton Pharma Services
Douglas
Corealis
Upperton
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Dosage Form Development Service 麻豆原创 Size (2020-2031)
2.1.2 Dosage Form Development Service 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Dosage Form Development Service by Country/Region (2020, 2024 & 2031)
2.2 Dosage Form Development Service Segment by Type
2.2.1 Pre-Formulation Services
2.2.2 Late Phase Formulation Development Services
2.3 Dosage Form Development Service 麻豆原创 Size by Type
2.3.1 Dosage Form Development Service 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Dosage Form Development Service 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Dosage Form Development Service Segment by Application
2.4.1 Oral Dosage Form
2.4.2 Injectable Dosage Form
2.4.3 Transdermal Dosage Form
2.4.4 Others
2.5 Dosage Form Development Service 麻豆原创 Size by Application
2.5.1 Dosage Form Development Service 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Dosage Form Development Service 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Dosage Form Development Service 麻豆原创 Size by Player
3.1 Dosage Form Development Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Dosage Form Development Service Revenue by Player (2020-2025)
3.1.2 Global Dosage Form Development Service Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Dosage Form Development Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Dosage Form Development Service by Region
4.1 Dosage Form Development Service 麻豆原创 Size by Region (2020-2025)
4.2 Global Dosage Form Development Service Annual Revenue by Country/Region (2020-2025)
4.3 Americas Dosage Form Development Service 麻豆原创 Size Growth (2020-2025)
4.4 APAC Dosage Form Development Service 麻豆原创 Size Growth (2020-2025)
4.5 Europe Dosage Form Development Service 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Dosage Form Development Service 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Dosage Form Development Service 麻豆原创 Size by Country (2020-2025)
5.2 Americas Dosage Form Development Service 麻豆原创 Size by Type (2020-2025)
5.3 Americas Dosage Form Development Service 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dosage Form Development Service 麻豆原创 Size by Region (2020-2025)
6.2 APAC Dosage Form Development Service 麻豆原创 Size by Type (2020-2025)
6.3 APAC Dosage Form Development Service 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Dosage Form Development Service 麻豆原创 Size by Country (2020-2025)
7.2 Europe Dosage Form Development Service 麻豆原创 Size by Type (2020-2025)
7.3 Europe Dosage Form Development Service 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Dosage Form Development Service by Region (2020-2025)
8.2 Middle East & Africa Dosage Form Development Service 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Dosage Form Development Service 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Dosage Form Development Service 麻豆原创 Forecast
10.1 Global Dosage Form Development Service Forecast by Region (2026-2031)
10.1.1 Global Dosage Form Development Service Forecast by Region (2026-2031)
10.1.2 Americas Dosage Form Development Service Forecast
10.1.3 APAC Dosage Form Development Service Forecast
10.1.4 Europe Dosage Form Development Service Forecast
10.1.5 Middle East & Africa Dosage Form Development Service Forecast
10.2 Americas Dosage Form Development Service Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Dosage Form Development Service Forecast
10.2.2 Canada 麻豆原创 Dosage Form Development Service Forecast
10.2.3 Mexico 麻豆原创 Dosage Form Development Service Forecast
10.2.4 Brazil 麻豆原创 Dosage Form Development Service Forecast
10.3 APAC Dosage Form Development Service Forecast by Region (2026-2031)
10.3.1 China Dosage Form Development Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Dosage Form Development Service Forecast
10.3.3 Korea 麻豆原创 Dosage Form Development Service Forecast
10.3.4 Southeast Asia 麻豆原创 Dosage Form Development Service Forecast
10.3.5 India 麻豆原创 Dosage Form Development Service Forecast
10.3.6 Australia 麻豆原创 Dosage Form Development Service Forecast
10.4 Europe Dosage Form Development Service Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Dosage Form Development Service Forecast
10.4.2 France 麻豆原创 Dosage Form Development Service Forecast
10.4.3 UK 麻豆原创 Dosage Form Development Service Forecast
10.4.4 Italy 麻豆原创 Dosage Form Development Service Forecast
10.4.5 Russia 麻豆原创 Dosage Form Development Service Forecast
10.5 Middle East & Africa Dosage Form Development Service Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Dosage Form Development Service Forecast
10.5.2 South Africa 麻豆原创 Dosage Form Development Service Forecast
10.5.3 Israel 麻豆原创 Dosage Form Development Service Forecast
10.5.4 Turkey 麻豆原创 Dosage Form Development Service Forecast
10.6 Global Dosage Form Development Service Forecast by Type (2026-2031)
10.7 Global Dosage Form Development Service Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Dosage Form Development Service Forecast
11 Key Players Analysis
11.1 Ascendia
11.1.1 Ascendia Company Information
11.1.2 Ascendia Dosage Form Development Service Product Offered
11.1.3 Ascendia Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Ascendia Main Business Overview
11.1.5 Ascendia Latest Developments
11.2 Recipharm
11.2.1 Recipharm Company Information
11.2.2 Recipharm Dosage Form Development Service Product Offered
11.2.3 Recipharm Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Recipharm Main Business Overview
11.2.5 Recipharm Latest Developments
11.3 Aurigene Services
11.3.1 Aurigene Services Company Information
11.3.2 Aurigene Services Dosage Form Development Service Product Offered
11.3.3 Aurigene Services Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Aurigene Services Main Business Overview
11.3.5 Aurigene Services Latest Developments
11.4 Pirama
11.4.1 Pirama Company Information
11.4.2 Pirama Dosage Form Development Service Product Offered
11.4.3 Pirama Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Pirama Main Business Overview
11.4.5 Pirama Latest Developments
11.5 厂别谤谩苍
11.5.1 厂别谤谩苍 Company Information
11.5.2 厂别谤谩苍 Dosage Form Development Service Product Offered
11.5.3 厂别谤谩苍 Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 厂别谤谩苍 Main Business Overview
11.5.5 厂别谤谩苍 Latest Developments
11.6 SGS
11.6.1 SGS Company Information
11.6.2 SGS Dosage Form Development Service Product Offered
11.6.3 SGS Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 SGS Main Business Overview
11.6.5 SGS Latest Developments
11.7 NerPharMa
11.7.1 NerPharMa Company Information
11.7.2 NerPharMa Dosage Form Development Service Product Offered
11.7.3 NerPharMa Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 NerPharMa Main Business Overview
11.7.5 NerPharMa Latest Developments
11.8 Scantox
11.8.1 Scantox Company Information
11.8.2 Scantox Dosage Form Development Service Product Offered
11.8.3 Scantox Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Scantox Main Business Overview
11.8.5 Scantox Latest Developments
11.9 Protheragen-ING
11.9.1 Protheragen-ING Company Information
11.9.2 Protheragen-ING Dosage Form Development Service Product Offered
11.9.3 Protheragen-ING Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Protheragen-ING Main Business Overview
11.9.5 Protheragen-ING Latest Developments
11.10 BDD Pharma
11.10.1 BDD Pharma Company Information
11.10.2 BDD Pharma Dosage Form Development Service Product Offered
11.10.3 BDD Pharma Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 BDD Pharma Main Business Overview
11.10.5 BDD Pharma Latest Developments
11.11 Evonik
11.11.1 Evonik Company Information
11.11.2 Evonik Dosage Form Development Service Product Offered
11.11.3 Evonik Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Evonik Main Business Overview
11.11.5 Evonik Latest Developments
11.12 Dalton Pharma Services
11.12.1 Dalton Pharma Services Company Information
11.12.2 Dalton Pharma Services Dosage Form Development Service Product Offered
11.12.3 Dalton Pharma Services Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Dalton Pharma Services Main Business Overview
11.12.5 Dalton Pharma Services Latest Developments
11.13 Douglas
11.13.1 Douglas Company Information
11.13.2 Douglas Dosage Form Development Service Product Offered
11.13.3 Douglas Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Douglas Main Business Overview
11.13.5 Douglas Latest Developments
11.14 Corealis
11.14.1 Corealis Company Information
11.14.2 Corealis Dosage Form Development Service Product Offered
11.14.3 Corealis Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Corealis Main Business Overview
11.14.5 Corealis Latest Developments
11.15 Upperton
11.15.1 Upperton Company Information
11.15.2 Upperton Dosage Form Development Service Product Offered
11.15.3 Upperton Dosage Form Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Upperton Main Business Overview
11.15.5 Upperton Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
